In recent years, gender dysphoria in minors has become a hotly debated topic. To address this issue, the Ministry of Health and Ministry of Family have initiated a joint discussion with the aim of developing new guidelines on the use of triptorelin, a puberty-blocking drug. The initiative is being led by Ministers Orazio Schillaci and Eugenia Roccella, who have assembled a team of technicians and experts to work together on this important project.
The joint statement from the two ministries highlights the work that has been done so far to address gender dysphoria and the use of blockers. The statement mentions the involvement of scientific societies, the National Bioethics Committee, and a survey conducted in various regions regarding the clinical and financial aspects of prescribing triptorelin. This collaborative effort aims to reexamine the issue of using triptorelin in cases of gender dysphoria in minors and establish clear guidelines for its use in the future.
The press release also outlines a request for a report from AIFA on the therapeutic indications for the drug. This collaborative effort will bring together experts from different fields to discuss this important topic and provide guidance on how best to approach this issue going forward. The composition of the expert panel will be finalized in the coming days to further advance this important discussion.
Overall, this joint initiative by the Ministry of Health and Ministry of Family is an important step towards addressing gender dysphoria in minors and ensuring that these children receive appropriate care. By bringing together experts from different fields and working collaboratively, we can develop clear guidelines that will help guide healthcare professionals in their treatment decisions going forward.
